Clinical trial

Pembrolizumab and Itacitinib (INCB039110) for Non-Small Cell Lung Cancer

NCT03425006

Study summary

ClinicalTrials.gov

Pembrolizumab and Itacitinib (INCB039110) for Non-Small Cell Lung Cancer

Design: INTERVENTIONAL · Status: TERMINATED · Phase: PHASE2

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Unmapped registry intervention Itacitinib Find medicine records · Find other trials using this name

BIOLOGICAL · Unmapped registry intervention Pembrolizumab Find medicine records · Find other trials using this name

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2018-06-18

PhasePHASE2

Conditions

Non Small Cell Lung Cancerunresolved

Interventions

ItacitinibDRUG

PembrolizumabBIOLOGICAL

Sponsors & collaborators

University of Pennsylvanialead sponsor

Mapped research locations

PhiladelphiaPennsylvania, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03425006 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.